| Outcome Measures: |
Primary: AUCGIR(0-60min), Baseline corrected area under the glucose infusion rate curve from 0 to 60 minutes after bolus administration, 60 minutes | Secondary: AUCins(0-30min), Baseline corrected area under the insulin concentration time curve from 0 to 30 minutes after bolus administration, 30 minutes|AUCins(0-60min), Baseline corrected area under the insulin concentration time curve from 0 to 60 minutes after bolus administration, 60 minutes|AUCins(0-600min), Baseline corrected area under the insulin concentration time curve from 0 to 600 minutes after bolus administration, 600 minutes|Cmax insulin, Maximum observed baseline corrected insulin concentration, 10 hours|Tmax insulin, Time from bolus administration to baseline corrected Cmax, 10 hours|TmaxGIR, Time from bolus administration to maximum baseline corrected glucose infusion rate, 10 hours|GIRmax, Maximum baseline corrected glucose infusion rate, 10 hours|Adverse Events, Number of Adverse Events in each arm, up to 8 weeks|Clinical safety laboratory, Haematology, biochemistry and urinalysis: changes and findings from Baseline in clinical safety laboratory parameters during the trial duration, from screening, and at follow-up visit., up to 8 weeks
|
